Related Experiment Video
Updated: Sep 14, 2025
Ex Vivo Infection of Live Tissue with Oncolytic Viruses
Published on: June 25, 2011
Oncolytic HSV and cancer drug interactions: Current clinical status and future directions
Karina Vázquez-Arreguín1, Kimberly A Rivera-Caraballo2, Divya Ventarapragada3
1Department of Pathology, Medical College of Georgia and Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA.
Abstract:
Oncolytic herpes simplex viruses (oHSVs) are engineered to target and replicate specifically in tumor cells, minimizing damage to normal tissues. This live virus biotherapy entails direct tumor cell killing followed by stimulation of antitumor immunity, leading to abscopal effects in untreated lesions. Currently, there are two clinically approved oHSV biotherapeutics: Imlygic, marketed by Amgen for the treatment of advanced melanoma in the United States and Europe, and Delytact, conditionally approved for recurrent brain tumors in Japan. Lessons learned from initial testing in patients have led to the development of second-generation viruses designed to improve tumor cytotoxicity and/or antitumor immune responses. Preclinical research has also uncovered numerous virus-drug interactions predicted to be synergistic. This has resulted in numerous clinical trials that are currently evaluating these second-generation viruses as single agents or in combination with other antineoplastic therapeutics. As of this review, there are more than 100 clinical trials evaluating their safety and efficacy. Here, we lay out a summary of oHSVs and the rationale behind various virus-drug combinations in clinical trials for patients with different malignancies. We provide a comprehensive review that details the underlying mechanisms of oHSV design and virus-drug interactions that form the basis of their clinical investigation.
Insights
Oncolytic herpes simplex viruses (oHSVs) are engineered viruses that kill tumor cells and stimulate anti-tumor immunity. Ongoing clinical trials explore combinations of these viruses with drugs to enhance cancer treatment efficacy.
Area of Science:
- Oncology
- Virology
- Immunotherapy
Background:
- Oncolytic herpes simplex viruses (oHSVs) are engineered viruses designed for targeted tumor cell destruction and immune stimulation.
- Current oHSV therapies include Imlygic for melanoma and Delytact for brain tumors, with ongoing development of second-generation viruses.
Purpose of the Study:
- To summarize the current landscape of oHSVs in cancer therapy.
- To review the rationale and mechanisms behind virus-drug combinations in clinical trials.
- To detail the design principles of oHSVs and their interactions with antineoplastic therapeutics.
Main Methods:
- Review of existing literature on oHSV development and clinical trials.
- Analysis of preclinical data on virus-drug interactions.
- Summary of ongoing clinical investigations for various malignancies.
Main Results:
- Second-generation oHSVs are being developed to enhance tumor cell killing and immune response.
- Numerous preclinical studies suggest synergistic interactions between oHSVs and various drugs.
- Over 100 clinical trials are evaluating oHSVs as monotherapy or in combination treatments.
Conclusions:
- oHSVs represent a promising biotherapy for various cancers, with significant potential when combined with other therapeutics.
- Understanding virus-drug interactions is crucial for optimizing oHSV-based cancer treatment strategies.
- The extensive clinical trial landscape indicates a strong focus on advancing oHSV therapies for improved patient outcomes.
Related Concept Videos
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:51Mechanisms of Retrovirus-induced Cancers
02:56Treatment Resistant Cancers